Ayala Pharmaceuticals Inc (ADXS)

[mypekeispooped]

From SA. I believe this biomarker will be of major importance in identifying those patients that can be helped the most:

"Advaxis, Inc (ADXS) is currently in pivotal study with its lead candidate, axalimogene filolisbac, for a variety of tumor types. However, the most advanced data we've seen to date was in advanced, recurrent cervical cancer, from the GOG-0265 study at the Society for Gynecologic Oncology meeting earlier this year.

Recently, ADXS announced that updated findings from this same study were selected for presentation at the European Society for Gynecologic Oncology meeting in November. Specifically, these findings will relate to the identification of a potential biomarker gene expression signature that points to patients having better outcomes overall while being treated with axalimogene filolisbac.

Lower levels of these 4 genes segregated a group of patients with 56% 12-month overall survival rate, while patients with higher levels saw 12-month OS rates of only 15%. One protein in particular, unidentified in the press release, is apparently a useful indicator of outcomes for patients.

Looking forward: While it's not the most groundbreaking finding, potential biomarkers of immunotherapy success are very important to find, and they remain elusive across the board. If ADXS has a way to delineate which patients will benefit from their therapy, it provides a major inroad toward demonstrating the value of their therapy. The 56% 12-month OS rate is substantially better than that seen among the entire patient population (38%), which was already favorable in comparison with historical controls."